**Core Concept:** Nephropathy is a term used to describe kidney disease, and in the context of patients with cancer, it usually refers to kidney damage caused by cancer therapy. The question is asking about the most common type of nephropathy seen in cancer patients among the given options.

**Why the Correct Answer is Right:** The correct answer, **D:** Hemolytic-uremic syndrome (HUS), is the most common nephropathy associated with cancer therapy. HUS is a rare but severe complication of cancer treatment, particularly with the use of monoclonal antibodies and some chemotherapy drugs. It occurs when the immune system attacks the blood cells, leading to hemolysis (destruction of red blood cells) and subsequent acute kidney injury.

**Why Each Wrong Option is Incorrect:**

A. **Nephrotoxicity (nephropathy):** Although nephrotoxicity is a possibility in cancer therapy, it refers to general kidney damage due to toxic substances, not specifically cancer-related nephropathy.

B. **Lupus nephritis:** This is a type of glomerulonephritis caused by autoimmune disease (Systemic Lupus Erythematosus), not directly related to cancer therapy.

C. **Adriamycin nephropathy:** Adriamycin is a chemotherapy drug, but it is not the most common nephropathy associated with cancer therapy. It is specific to the use of Adriamycin and other anthracycline antibiotics.

**Clinical Pearl:** Understanding the various types of nephropathy, including cancer-related nephropathy, is crucial for clinicians treating cancer patients. Early recognition and management of these complications can improve patient outcomes and quality of life.